Syntimmune, Inc.
Biotechnology company · New York, United States
Syntimmune, Inc. is a biotechnology company headquartered in New York, United States. Its earliest recorded incorporation is in 2013. It has reported private securities offerings to the US SEC, most recently $18 million sold in a notice filed in 2017.
Syntimmune at a glance
What does Syntimmune do?
Private fundraising reported to the SEC
2 Form D notices; the most recent reported $18 million sold (2017).
Frequently asked questions about Syntimmune
Where is Syntimmune headquartered?
Syntimmune, Inc. is headquartered in New York, United States.
What does Syntimmune do?
Syntimmune, Inc. is a biotechnology company.
When was Syntimmune founded?
The earliest incorporation on record for Syntimmune, Inc. is in 2013, according to public company registers.
Similar companies
- Lexeo Therapeutics, Inc.New York City, New York, United States
- MiNK Therapeutics, Inc.New York City, New York, United States
- IN8BIO, Inc.New York City, New York, United States
- Anavex Life Sciences Corp.New York City, New York, United States
- Brainstorm Cell Therapeutics Inc.New York City, New York, United States
- Bioincept LLCNew York City, New York, United States
- Protara Therapeutics, Inc.New York City, New York, United States
- Ancilia Biosciences, Inc.New York City, New York, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-23. Data licences